Research Library

Kartika et al. (2024) — European journal of haematology

In a retrospective cohort of 95 adults on veno-venous ECMO, bivalirudin, compared with heparin, was associated with fewer thrombotic events (HR 0.14) and red-cell and platelet transfusions, with no difference in major bleeding.

Read analysis →

Pappalardo et al. (2012) — Minerva anestesiologica

A retrospective analysis of 27 ventricular assist device patients with heparin-induced thrombocytopenia found argatroban achieved adequate anticoagulation at reduced doses, with procedural success in 81% and outcomes significantly improved versus historical lepirudin controls.

Read analysis →

Alvarez et al. (2007) — Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine

This case report describes an unusual presentation of heparin-induced thrombocytopenia in which thrombocytopenia was absent despite the immune-mediated, extreme prothrombotic state that characterizes this complication of heparin therapy.

Read analysis →

Jia et al. (2021) — Journal of clinical and translational hepatology

In 134 Chinese patients undergoing coronary angiography with or without PCI, bivalirudin (n=66) was associated with improved kidney function markers, particularly in moderate-to-severe chronic kidney disease, while unfractionated heparin (n=68) may cause less liver enzyme elevation.

Read analysis →

Li et al. (2025) — CNS neuroscience & therapeutics

In a propensity-matched analysis of a prospective MRI cohort of 467 patients with acute branch atheromatous disease stroke, argatroban was not associated with excellent 90-day outcome (60.0% vs 64.2%; OR 0.84).

Read analysis →

Yan et al. (2025) — Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

In a weighted cohort of Chinese patients with mild-to-moderate ischemic stroke from large artery atherosclerosis, argatroban added to antiplatelet therapy within 72 hours improved 90-day functional outcome (mRS 0-2: 85.3% vs 74.5%) without increased bleeding risk.

Read analysis →

Huffman et al. (2024) — American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

This case report describes a 62-year-old man who developed profound IgG-mediated thrombocytopenia five days after starting eptifibatide, with platelet recovery after discontinuation and a switch to argatroban.

Read analysis →

Matsuoka et al. (2025) — International journal of cardiology

Analysis of 7,239 non-valvular atrial fibrillation patients from the DIRECT-Extend registry found that declining creatinine clearance was linked to higher ischemic and bleeding risks, with patterns differing across dabigatran, rivaroxaban, edoxaban, warfarin, and apixaban.

Read analysis →

Koh et al. (2025) — Asian cardiovascular & thoracic annals

In a propensity-matched cohort of 766 Asian patients with non-valvular atrial fibrillation, direct oral anticoagulants were associated with lower risk of significant eGFR decline and worsened CKD stage than warfarin; rivaroxaban and dabigatran, but not apixaban, showed benefit.

Read analysis →

Atreja et al. (2025) — Advances in therapy

Among 171,700 Medicare patients with non-valvular atrial fibrillation who switched from warfarin to a direct oral anticoagulant, propensity-matched analysis found lower stroke/systemic embolism and major bleeding rates with apixaban than with dabigatran or rivaroxaban.

Read analysis →

Konecki et al. (2024) — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

A two-compartment population PK-PD model was developed in 668 patients undergoing radiofrequency ablation, identifying baseline ACT, initial unfractionated heparin dose, and prior anticoagulant use as main predictors of activated clotting time at 15 minutes.

Read analysis →

Wu et al. (2024) — Journal of the American Heart Association

In a national health insurance cohort of 78,805 atrial fibrillation patients on DOACs, concomitant amiodarone (especially with dabigatran) was associated with increased major and intracranial bleeding, while propafenone, dronedarone, flecainide, and sotalol showed no significant excess risk.

Read analysis →

Waseem et al. (2026) — Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

A network meta-analysis of 16 studies and 1,403 cerebral venous thrombosis patients found DOACs (apixaban, dabigatran, rivaroxaban) had outcomes comparable to vitamin K antagonists, with apixaban ranking highest for reducing VTE recurrence, mortality, and hemorrhagic events.

Read analysis →

Huang et al. (2025) — Frontiers in cardiovascular medicine

A 32-year-old man developed mesenteric venous thrombosis and pulmonary embolism during COVID-19 and was found to carry a heterozygous PROS1 missense mutation (c.683G>A, p.Cys228Tyr); treatment with low-molecular-weight heparin followed by rivaroxaban showed no VTE recurrence over one year of follow-up.

Read analysis →

Yuan et al. (2025) — Journal of orthopaedic surgery and research

In 655 total knee arthroplasty patients, postoperative hemoglobin declined by a mean 13.9 g/L within the first week, with rivaroxaban and low-molecular-weight heparin associated with greater reductions than aspirin, though effect sizes were small.

Read analysis →

Takano et al. (2026) — Cureus

A 75-year-old Japanese woman with left upper-extremity swelling was diagnosed with subclavian vein thrombosis secondary to metastatic gastric adenocarcinoma; unfractionated heparin relieved symptoms before transition to apixaban, and she died nine months later from disease progression.

Read analysis →

Riess et al. (2021) — Critical reviews in oncology/hematology

This review summarizes trial evidence supporting direct oral anticoagulants (apixaban, edoxaban, rivaroxaban) as alternatives to low-molecular-weight heparin for cancer-associated thrombosis, noting real-world persistence issues with subcutaneous LMWH and patient-level factors affecting anticoagulant choice.

Read analysis →

Cosmi (2021) — Expert opinion on pharmacotherapy

This review of cancer-associated thrombosis finds direct oral anticoagulants non-inferior to low-molecular-weight heparin for treatment, though rivaroxaban and edoxaban showed higher bleeding rates, especially in gastrointestinal cancers; prophylaxis trials reduced VTE but increased bleeding.

Read analysis →

Kimpton et al. (2019) — Expert opinion on drug safety

This narrative review assesses edoxaban, rivaroxaban, and apixaban for cancer-associated thrombosis, concluding these factor Xa inhibitors are effective and convenient, possibly lowering recurrent VTE risk, though gastrointestinal malignancies carry heightened major bleeding risk.

Read analysis →

Park et al. (2026) — Annals of laboratory medicine

In 459 Korean atrial fibrillation patients taking apixaban, edoxaban, or rivaroxaban, peak and trough plasma concentrations varied widely, with substantial proportions falling outside predicted ranges based on pharmacokinetic data, suggesting need for population-specific reference ranges.

Read analysis →

Cichewicz et al. (2025) — Future cardiology

A Bayesian network meta-analysis of 33 European real-world studies in non-valvular atrial fibrillation found DOACs generally outperformed vitamin K antagonists, with edoxaban showing similar effectiveness and lower major bleeding and intracranial hemorrhage versus rivaroxaban.

Read analysis →

Borgonovo et al. (2024) — Cureus

An 82-year-old man with hepatocellular carcinoma developed fatal vanishing bile duct syndrome weeks after starting edoxaban for non-valvular atrial fibrillation, representing the first reported case of acute VBDS possibly linked to this factor Xa inhibitor.

Read analysis →

Petch et al. (2024) — Scientific reports

A deep reinforcement-learning model for warfarin dosing, trained on 22,502 atrial fibrillation patients from three DOAC trials, was externally validated on 5,730 RE-LY patients: center-level algorithm-consistent dosing was associated with improved time in therapeutic INR range and fewer composite clinical outcomes.

Read analysis →

Pereira et al. (1998) — British journal of plastic surgery

Case report of clinically significant Serratia marcescens infection transmitted by medicinal leeches applied after complex hand injury, showing leeches can carry this pathogen in addition to Aeromonas hydrophila, with implications for prophylaxis.

Read analysis →